De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Carna Biosciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Carna Biosciences heeft een totaal eigen vermogen van ¥3.2B en een totale schuld van ¥88.0M, wat de schuld-eigenvermogensverhouding op 2.7% brengt. De totale activa en totale passiva bedragen respectievelijk ¥3.7B en ¥471.0M.

Belangrijke informatie

2.7%

Verhouding schuld/eigen vermogen

JP¥88.00m

Schuld

Rente dekkingsratio	n/a
Contant	JP¥3.03b
Aandelen	JP¥3.21b
Totaal verplichtingen	JP¥471.00m
Totaal activa	JP¥3.69b

Recente financiële gezondheidsupdates

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

Recent updates

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Aug 06

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ¥3.5B ) 4572 } overtreffen de korte termijn passiva ( ¥370.0M ).

Langlopende schulden: De kortetermijnactiva 4572 ( ¥3.5B ) overtreffen de langetermijnschulden ( ¥101.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 4572 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 4572 is de afgelopen 5 jaar gedaald van 19.8% naar 2.7%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 4572 heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: 4572 heeft voldoende kasruimte voor 2.1 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 14.9 % per jaar.

Carna Biosciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Recent updates

Carna Biosciences, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

New major risk - Share price stability

Carna Biosciences, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥23.21 loss per share (vs JP¥32.77 loss in 1Q 2023)

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Carna Biosciences, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: JP¥68.57 loss per share (vs JP¥99.07 loss in FY 2022)

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥20.13 loss per share (vs JP¥31.91 loss in 3Q 2022)

Carna Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: JP¥21.43 loss per share (vs JP¥25.25 loss in 2Q 2022)

Carna Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: JP¥32.77 loss per share (vs JP¥1.12 loss in 1Q 2022)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc. to Report Q4, 2022 Results on Feb 10, 2023

Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Carna Biosciences, Inc. announced that it expects to receive ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Third quarter 2022 earnings released: JP¥31.91 loss per share (vs JP¥31.70 loss in 3Q 2021)

Carna Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: JP¥25.25 loss per share (vs JP¥39.45 loss in 2Q 2021)

Carna Biosciences, Inc. to Report Q2, 2022 Results on Aug 05, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Carna Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Consensus revenue estimates increase by 40%

Third quarter 2021 earnings released: JP¥31.70 loss per share (vs JP¥20.32 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥39.45 loss per share (vs JP¥17.31 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥23.06 loss per share (vs JP¥15.22 loss in 1Q 2020)

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: JP¥1,433

Carna Biosciences, Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

New 90-day low: JP¥1,148

Third quarter 2020 earnings released: JP¥20.32 loss per share

New 90-day low: JP¥1,294

Carna Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low - JP¥1,371

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven